HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

• Published in: Oncotarget 2016-10, Vol.7 (42), p.69060-69074
• Main Authors: Fanotto, Valentina, Ongaro, Elena, Rihawi, Karim, Avallone, Antonio, Silvestris, Nicola, Fornaro, Lorenzo, Vasile, Enrico, Antonuzzo, Lorenzo, Leone, Francesco, Rosati, Gerardo, Giuliani, Francesco, Bordonaro, Roberto, Scartozzi, Mario, De Maglio, Giovanna, Negri, Francesca V, Fasola, Gianpiero, Aprile, Giuseppe
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - metabolism; Animals; Antineoplastic Agents - pharmacology; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Male; Mice; Palliative Care; Prognosis; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - metabolism; Review; Signal Transduction; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; Stomach Neoplasms - metabolism
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.11264

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.